Prestige Consumer Healthcare Inc. (NYSE:PBH) Short Interest Up 18.0% in February

Prestige Consumer Healthcare Inc. (NYSE:PBH) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 2,374,940 shares, a growth of 18.0% from the February 12th total of 2,011,903 shares. Currently, 5.1% of the company’s stock are short sold. Based on an average daily volume of 464,756 shares, the days-to-cover ratio is currently 5.1 days. Based on an average daily volume of 464,756 shares, the days-to-cover ratio is currently 5.1 days. Currently, 5.1% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PBH. Jefferies Financial Group reduced their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $80.60.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC lifted its stake in Prestige Consumer Healthcare by 4.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Prestige Consumer Healthcare in the 3rd quarter valued at $1,890,000. AXQ Capital LP acquired a new position in Prestige Consumer Healthcare in the 2nd quarter valued at $694,000. Tributary Capital Management LLC raised its position in Prestige Consumer Healthcare by 157.3% during the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock worth $23,675,000 after buying an additional 231,969 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Prestige Consumer Healthcare by 30.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock worth $28,656,000 after acquiring an additional 106,224 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 1.9%

Shares of PBH stock traded down $1.17 during trading hours on Wednesday, reaching $61.13. 169,094 shares of the stock were exchanged, compared to its average volume of 395,243. The business’s fifty day moving average is $66.00 and its two-hundred day moving average is $63.40. The firm has a market capitalization of $2.89 billion, a P/E ratio of 16.16, a P/E/G ratio of 1.92 and a beta of 0.41. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $89.37. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. During the same quarter in the prior year, the firm earned $1.22 EPS. The firm’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, research analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).